Deerfield Management Company, L.P. (Series C) Veracyte, Inc. Transaction History
Deerfield Management Company, L.P. (Series C)
- $5.38 Billion
- Q3 2024
A detailed history of Deerfield Management Company, L.P. (Series C) transactions in Veracyte, Inc. stock. As of the latest transaction made, Deerfield Management Company, L.P. (Series C) holds 12,032 shares of VCYT stock, worth $432,430. This represents 0.01% of its overall portfolio holdings.
Number of Shares
12,032Holding current value
$432,430% of portfolio
0.01%Shares
2 transactions
Others Institutions Holding VCYT
# of Institutions
308Shares Held
81.8MCall Options Held
134KPut Options Held
13.3K-
Black Rock Inc. New York, NY7.79MShares$280 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.75MShares$278 Million0.0% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI5.02MShares$181 Million0.27% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl4.92MShares$177 Million1.59% of portfolio
-
Wellington Management Group LLP Boston, MA4.23MShares$152 Million0.03% of portfolio
About VERACYTE, INC.
- Ticker VCYT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 71,575,904
- Market Cap $2.57B
- Description
- Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...